Re: Zenith Capital Corp. to Present on the Emerging Growth Conference on September 25, 2024
posted on
Oct 08, 2024 03:53PM
Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials
Agreed Fuzzy, one would hope that eventually DM we get tired of his lack of management business success and realize he needs to recruit top end experienced biotech managment and move both Zenith and RVX to the next level for getting a major deal and proper non dilutive financing because it aint happening with him at the helm!!, You listening Don, how long you going to wait this out....